Navigating Next-Generation Antibody Discovery Platforms in a Complex IP Landscape
As antibody therapeutics evolve toward increasingly complex and modular formats—including multispecifics, cell engagers, and engineered immune cell therapies—discovery platforms must meet higher standards for quality, scalability, and clinical relevance. Modern biologics development requires platforms that consistently deliver highly developable, fully human antibodies and support efficient translation to the clinic.
Nona Biosciences operates and continuously advances the Harbour Mice® platforms, a family of fully human antibody discovery platforms built on ongoing innovation, integration, and validation. Through multi-generation platform evolution, advanced genome engineering, high-throughput screening, and AI-enabled analytics, Nona has built a robust, data-driven ecosystem. This ecosystem enables the efficient discovery of fully human HCAbs and derived VH domains that are optimized for next-generation therapeutic modalities.
This article highlights the evolution of Nona Biosciences’ Harbour Mice® platforms, demonstrating how sustained platform innovation, strategic IP development, and real‑world validation through data and partnerships set the standard for modern antibody discovery. It also underscores why partner selection should prioritize current capabilities and future‑focused innovation, rather than legacy comparisons.
Platform Evolution Is Fundamental, Not Optional
Foundational antibody discovery platforms played a critical role in enabling the first wave of therapeutic antibodies. However, as with all enabling technologies, early implementations were never intended to remain static.
At Nona Biosciences, Harbour Mice® platforms have undergone multiple generations of continuous innovation, evolving from early foundational designs to advanced systems engineered for improved immune repertoire diversity, antibody quality, and translational relevance. Each generation reflects advances in genetic engineering, immune system optimization, screening methodologies, and downstream analytics.
Early generations of Harbour Mice® utilized transgenic approaches that were state-of-the-art at the time and enabled initial access to fully human antibody repertoires in vivo. As genetic engineering technologies advanced, Nona continuously integrated more precise and scalable approaches to further enhance platform performance. Today’s Harbour Mice® platforms incorporate advanced genome engineering strategies that improve control over antibody expression, immune titers, and repertoire quality—resulting in meaningful gains in antibody diversity, affinity, biophysical properties, and the efficiency of generating highly developable therapeutic candidates.
Crucially, no single historical technique defines the Harbour Mice® platform. Sustained differentiation comes from the ability to integrate new technologies across biology, engineering, and computation as the field evolves. As a result, the value of an antibody discovery platform must be assessed based on current performance and future readiness, rather than legacy configurations.
This continuous platform evolution is supported by a forward-looking intellectual property framework designed to protect innovation across generations. Newer Harbour Mice® platforms are independently protected, with ongoing filings aligned to emerging capabilities—ensuring that technological progress and IP strategy advance in parallel and providing partners with confidence in long-term collaboration.
Platform Evolution Is Fundamental, Not Optional
Foundational antibody discovery platforms played a critical role in enabling the first wave of therapeutic antibodies. However, as with all enabling technologies, early implementations were never intended to remain static.
At Nona Biosciences, Harbour Mice® platforms have undergone multiple generations of continuous innovation, evolving from early foundational designs to advanced systems engineered for improved immune repertoire diversity, antibody quality, and translational relevance. Each generation reflects advances in genetic engineering, immune system optimization, screening methodologies, and downstream analytics.
Early generations of Harbour Mice® utilized transgenic approaches that were state-of-the-art at the time and enabled initial access to fully human antibody repertoires in vivo. As genetic engineering technologies advanced, Nona continuously integrated more precise and scalable approaches to further enhance platform performance. Today’s Harbour Mice® platforms incorporate advanced genome engineering strategies that improve control over antibody expression, immune titers, and repertoire quality—resulting in meaningful gains in antibody diversity, affinity, biophysical properties, and the efficiency of generating highly developable therapeutic candidates.
Crucially, no single historical technique defines the Harbour Mice® platform. Sustained differentiation comes from the ability to integrate new technologies across biology, engineering, and computation as the field evolves. As a result, the value of an antibody discovery platform must be assessed based on current performance and future readiness, rather than legacy configurations.
This continuous platform evolution is supported by a forward-looking intellectual property framework designed to protect innovation across generations. Newer Harbour Mice® platforms are independently protected, with ongoing filings aligned to emerging capabilities—ensuring that technological progress and IP strategy advance in parallel and providing partners with confidence in long-term collaboration.
Technology Advancements Driving Evolution of Next-Gen Platforms
Early antibody mouse platforms, including early Harbour Mice® generations, utilized BAC-based transgenic approaches, which were state-of-the-art at the time. As genetic engineering technologies advanced, Harbour BioMed continuously adopted next-generation precision approaches, including CRISPR-enabled strategies, to further refine genomic integration, control expression, and improve immune repertoire outcomes. This evolution reflects a broader trend across biotechnology: modern platforms are defined not by a single historical method, but by their ability to integrate new technologies to drive better scientific and translational outcomes.
Data, SBC, and AI: A Compounding Advantage at Nona
The ultimate measure of an antibody discovery platform is not theoretical design, but real-world validation and performance over time.
At Nona Biosciences, Harbour Mice® platforms—particularly fully human HCAb platforms—are supported by extensive longitudinal datasets generated through years of internal programs and collaborations with global pharmaceutical partners. This depth of data enables a powerful feedback loop for continuous platform improvement.
By integrating high-throughput Single B Cell (SBC) screening with AI-enabled analytics through Hu-mAtrIx™, Nona has created a discovery ecosystem in which biological data, computational learning, and platform refinement reinforce one another. This integration has led to step-change improvements in discovery efficiency, success rates, and antibody developability.
In the AI era, data quality and scale compound over time, creating durable advantages that are increasingly difficult to replicate through single technology breakthroughs.
Broad Applicability and End-to-End Enablement
Beyond antibody discovery, Nona Biosciences provides integrated, end-to-end capabilities supporting a wide range of therapeutic modalities, including monoclonal antibodies, multispecifics, T-cell engagers, CAR-based therapies, and emerging delivery platforms.
The combination of Harbour Mice® platforms, in vivo discovery, SBC screening, and AI-driven optimization enables partners to progress efficiently from target concept to clinical candidates within a unified and scalable ecosystem.
Conclusion: Choosing the Right Partner Beyond IP
Innovation-driven discovery platforms must be evaluated through the lens of evolution, validation, and future readiness. While tools and technologies are essential, it is the expertise and execution capability of the partner operating those platforms that ultimately enable breakthrough therapies.
Through the integration of Harbour Mice® platforms with Nona Biosciences’ scientific expertise, data infrastructure, and AI capabilities, Nona has established a continuously advancing, clinically validated antibody discovery ecosystem—positioned to support the next generation of increasingly complex biotherapeutics.
Scientific innovation is inherently iterative. Platforms—and partners—that continue to evolve technically, computationally, and translationally are best positioned to deliver the next generation of biotherapeutics.
Related Resources
To explore some of the key technologies behind our Integrated Antibody Discovery Platforms:
- Download our Poster on Hu-mAtrIx™ AI–enabled Antibody Discovery for a concise, visual overview of how data and AI-enabled analytics are integrated to support continuous platform refinement and improved discovery outcomes
- Read our White Paper on Fully Human HCAbs and VH domains for a deeper discussion on why HCAb-derived VH formats serve as foundational building blocks for next-generation therapeutic modalities
